trending Market Intelligence /marketintelligence/en/news-insights/trending/ewkk2vcvom-_pr6_m4nwog2 content esgSubNav
In This List

Report: Allergan to sell women's health, infectious disease units

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: Allergan to sell women's health, infectious disease units

Allergan PLC is selling its women's health and infectious disease businesses after completing its strategic review, CNBC reported, citing sources familiar with the matter.

The Dublin-based company was reportedly weighing the sale of its women's health unit in April following confirmation that the company was undergoing a strategic review process.

The Botox maker evaluated transactions including share repurchases, selling certain business units, splitting the company, entering M&A deals and continuing its current business strategy to create shareholder value.

"We have a strong view both of our women's health and anti-infectives business, but they are less strategically important," Allergan's Chairman, President and CEO Brent Saunders previously said in the company's first-quarter 2018 earnings call.

Analysts from Cowen valued the business at $4 billion, while the infectious disease unit is at $2 billion.